Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04532190

Finding Alternatives to Standard Treatment for Attention-Deficit Hyperactivity Disorder

Attention-Deficit/Hyperactivity Disorder (ADHD) is characterized by poor attention, impulsivity, hyperactivity and emotional-motivational dysregulation. Here, we will test if theta burst repetitive transcranial magnetic stimulation (rTMS) can reduce the symptoms of ADHD.

Recruiting

Interested in participating?

Request Info

Key information

Age range

9 year–15 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

Background & Rationale Attention-Deficit/Hyperactivity Disorder (ADHD) is characterized by poor attention, impulsivity, hyperactivity and emotional-motivational dysregulation. It has an estimated prevalence of 5% in children. Usually, ADHD in children is treated with stimulant medications, such as methylphenidate. However, these pharmacotherapy treatments have numerous unwanted side effects, including sleep disturbances, appetite changes, and emotional lability, and do not prove to be effective in every case.

A promising and alternative option for reducing ADHD symptoms is non-invasive brain stimulation. Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive brain stimulation which involves the application of a magnetic field to the skull to change the behaviour and function of underlying brain areas. In turn, rTMS leads to positive long-term changes in neurochemical activity, and while studies are limited, some have shown that rTMS can reduce ADHD symptoms in adolescents with ADHD.

Methods Design: Open label TMS trial Primary Outcome: To examine the effect of active rTMS to the right prefrontal cortex on attention as measured by the TEACh-2

Outline:

  • Baseline Assessment (MRI Scan, assessment scales, neuropsychological testing)
  • rTMS intervention: 5 / week for 4 weeks.
  • Post-intervention Assessment (MRI Scan, assessment scales, neuropsychological testing).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of ADHD
  • 9-15 years old
  • IQ greater than 80
  • English fluency (to enable consent/assent)
  • If on medication, must have been on the same type and dosage for at least 3 months.

Exclusion criteria

  • Diagnosis of mania, psychosis, or bipolar disorder
  • Impediments to TMS or MRI (i.e. metal implants in body)
  • Prior electroconvulsive therapy or vagus nerve stimulation
  • Diagnosis of Autism Spectrum Disorder.

Treatment and study plan

rTMS

Device

Repetitive transcranial magnetic stimulation (rTMS)

Primary outcomes

  1. TEACH-2

    Time frame: Baseline to week 5

    Test of everyday attention in children - 2. Direct assessment of attention abilities in children.

Secondary outcomes

  1. SNAP-18

    Time frame: 5 weeks and 52 weeks.

    Parent reporting of ADHD symptom severity

  2. PedsQL

    Time frame: Baseline to week 5

    Self reporting of quality of life

Sponsors and collaborators

Lead sponsor

University of Calgary

Other

Registry information

Acronym: FAST-ADHD

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 31, 2020
Registry last updated
May 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.